Skip to main navigation
  • Contact Us
  • Global
    • International
    • Canada
    • France
    • Germany
    • Italy
    • Japan
    • Netherlands
    • Spain
Amicus Therapeutics
  • About Amicus
    • About Amicus
    • Chairman’s Welcome
    • Leadership
    • Belief Statement
    • Contact Us
    • Message from BIO
  • Patient Advocacy
    • Patient Advocacy
    • Disease Information
    • Rare Stories
    • Patient Advisory Boards
    • Corporate Giving
    • Resources
    • Expanded Access
  • Programs & Pipeline
    • Programs & Pipeline
    • Our Pipeline
    • Fabry Disease
    • Pompe Disease
    • Batten Disease
    • Additional Preclinical Programs
    • Clinical Trials
    • Platform Technologies
    • Journal Articles
    • Publications & Posters
  • Product
    • Product
    • Galafold®
    • Amicus Assist™
  • Responsibility
    • Responsibility
    • Ethics & Compliance
    • Global Medical Affairs
    • Corporate Giving
    • Healing Beyond Disease
    • ESG Report
  • Investors & Media
    • Investors & Media
    • Investor Relations
    • Senior Management Team
    • Board of Directors
    • Corporate Governance
    • Press Releases
    • Events & Presentations
    • Annual Reports and Proxies
    • SEC Filings
    • Stock Performance
    • Investor FAQs
    • Contact Us
    • Sign Up for Email Alerts
    • Featured Coverage
    • Electronic Press Kit
  • Careers
    • Careers
    • Overview
    • Search

Investors

Press Releases

Press Releases

May 10, 2022
Amicus Therapeutics Receives Notification of PDUFA Date Extensions for AT-GAA
May 9, 2022
Amicus Therapeutics Announces First Quarter 2022 Financial Results
May 4, 2022
Amicus Therapeutics to Present at the Bank of America 2022 Healthcare Conference
April 26, 2022
Amicus Therapeutics to Announce First Quarter 2022 Financial Results on May 9, 2022
April 19, 2022
Amicus Announces Issuance of New U.S. Composition of Matter Patent for Galafold® (migalastat), Strengthening Patent Protection Through 2038
March 16, 2022
Amicus Therapeutics Announces Positive Long-Term Data from Phase 1/2 Study of AT-GAA in Pompe Disease at the 2022 MDA Clinical & Scientific Conference
March 10, 2022
Amicus Therapeutics Announces Presentation and Posters at the 2022 MDA Clinical & Scientific Conference
March 1, 2022
Amicus Therapeutics to Present at the Cowen 42nd Annual Health Care Conference
February 24, 2022
Amicus Therapeutics Announces Full-Year 2021 Financial Results and Corporate Updates
February 10, 2022
Amicus Therapeutics to Announce Full-Year 2021 Financial Results on February 24, 2022

Pagination

  • Current page 1
  • Page 2
  • Next page next ›
  • Last page last »
  • About Amicus
    • Chairman’s Welcome
    • Leadership
    • Belief Statement
    • Contact Us
    • Message from BIO
  • Patient Advocacy
    • Disease Information
    • Rare Stories
    • Patient Advisory Boards
    • Corporate Giving
    • Resources
    • Expanded Access
  • Programs & Pipeline
    • Pipeline
    • Our Programs
    • Clinical Trials
    • Platform Technologies
    • Publications & Posters
    • Journal Articles
  • Product
    • Overview
    • Amicus Assist™
  • Responsibility
    • Ethics & Compliance
    • Global Medical Affairs
    • Corporate Giving
    • Healing Beyond Disease
    • ESG Report
  • Investors & Media
    • Corporate Governance
    • Press Releases
    • Events & Presentations
    • Annual Reports & Proxies
    • SEC Filings
    • Stock Performance
    • Investor FAQs
    • Featured Coverage
  • Careers
    • Overview
    • Search
  • Social Media
    • Twitter
    • YouTube
    • LinkedIn
Copyright © 2022 Amicus Therapeutics. All rights reserved. NP-AT-ALL-00011119
  • Cookies Statement
  • Terms of Use
  • Privacy Notice
  • Privacy Shield Policy

The site you are about to enter is intended for US healthcare professionals.

Please confirm you are a US healthcare professional.

I am a US healthcare professional I am not a US healthcare professional